Could immunotherapy let some stomach cancer patients skip surgery?
NCT ID NCT07646574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and surgery. Researchers will track how long participants remain cancer-free and overall survival. This approach aims to reduce the need for invasive procedures and improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab and Tremelimumab (immunotherapy drugs)
- What this could lead to
- If successful, this could offer a way to treat dMMR/MSI-H gastric cancer without surgery, reducing recovery time and preserving stomach function.
- What could go wrong
- This is a small, early-phase study with only 12 participants, so results may not apply broadly. Immunotherapy can cause serious side effects, and the cancer may still return without surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SURGICAL MANAGEMENT;DMMR/MSI-H GASTRIC CANCER;NEOADJUVANT IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.